Can Alzheimer disease be a form of type 3 diabetes?

Alzheimer disease (AD) and metabolic syndrome are two highly prevalent pathological conditions of Western society due to incorrect diet, lifestyle, and vascular risk factors. Recent data have suggested metabolic syndrome as an independent risk factor for AD and pre-AD syndrome. Furthermore, biological plausibility for this relationship has been framed within the "metabolic cognitive syndrome" concept. Due to the increasing aging of populations, prevalence of AD in Western industrialized countries will rise in the near future. Thus, new knowledge in the area of molecular biology and epigenetics will probably help to make an early molecular diagnosis of dementia. An association between metabolic syndrome and specific single-nucleotide polymorphisms (SNPs) in the gene INPPL1, encoding for SHIP2, a SH2 domain-containing inositol 5-phosphatase involved in insulin signaling, has been described. According to recent data suggesting that Type 2 diabetes represents an independent risk factor for AD and pre-AD, preliminary results of a case-control study performed to test the putative association between three SNPs in the SHIP2 gene and AD show a trend toward association of these SNPs with AD.

[1]  M. Chao,et al.  Insulin, insulin-like growth factor II, and nerve growth factor effects on tubulin mRNA levels and neurite formation. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[2]  E. Ferrannini,et al.  Essential hypertension, metabolic disorders, and insulin resistance. , 1991, American heart journal.

[3]  K. Angelides,et al.  Effects of insulin and insulin-like growth factors on neurofilament mRNA and tubulin mRNA content in human neuroblastoma SH-SY5Y cells. , 1992, Brain research. Molecular brain research.

[4]  M. Raizada,et al.  The cellular and physiological actions of insulin in the central nervous system , 1993, Neurochemistry International.

[5]  S. Yoshida,et al.  Insulin prevents apoptosis of external granular layer neurons in rat cerebellar slice cultures , 1995, Neuroscience Letters.

[6]  T. Niu,et al.  An extreme-sib-pair genome scan for genes regulating blood pressure. , 1999, American journal of human genetics.

[7]  P. Vollenweider,et al.  An SH2 Domain-Containing 5′ Inositolphosphatase Inhibits Insulin-Induced GLUT4 Translocation and Growth Factor-Induced Actin Filament Rearrangement , 1999, Molecular and Cellular Biology.

[8]  A. Hofman,et al.  Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. , 2000, Neurology.

[9]  Joseph B. Rayman,et al.  The Finland-United States investigation of non-insulin-dependent diabetes mellitus genetics (FUSION) study. I. An autosomal genome scan for genes that predispose to type 2 diabetes. , 2000, American journal of human genetics.

[10]  M. Racchi,et al.  Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase‐dependent pathway , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  H. Ishihara,et al.  SH2-containing inositol phosphatase 2 negatively regulates insulin-induced glycogen synthesis in L6 myotubes , 2001, Diabetologia.

[12]  S. Schurmans,et al.  The lipid phosphatase SHIP2 controls insulin sensitivity , 2001, Nature.

[13]  T. Asano,et al.  Overexpression of SH2-Containing Inositol Phosphatase 2 Results in Negative Regulation of Insulin-Induced Metabolic Actions in 3T3-L1 Adipocytes via Its 5′-Phosphatase Catalytic Activity , 2001, Molecular and Cellular Biology.

[14]  H. Ishihara,et al.  Association of SH2-containing inositol phosphatase 2 with the insulin resistance of diabetic db/db mice. , 2002, Diabetes.

[15]  Ling Xie,et al.  Alzheimer's β-Amyloid Peptides Compete for Insulin Binding to the Insulin Receptor , 2002, The Journal of Neuroscience.

[16]  P. Wilson,et al.  A genome scan for loci linked to quantitative insulin traits in persons without diabetes: the Framingham Offspring Study , 2003, Diabetologia.

[17]  G. Hart,et al.  O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. C. Torre.  Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics , 2004, The Lancet Neurology.

[19]  J. Levy,et al.  Polymorphisms in type II SH2 domain-containing inositol 5-phosphatase (INPPL1, SHIP2) are associated with physiological abnormalities of the metabolic syndrome. , 2004, Diabetes.

[20]  J. Shaw,et al.  The metabolic syndrome: prevalence in worldwide populations. , 2004, Endocrinology and metabolism clinics of North America.

[21]  D. Porte,et al.  Insulin signaling in the central nervous system: a critical role in metabolic homeostasis and disease from C. elegans to humans. , 2005, Diabetes.

[22]  J. Wands,et al.  Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? , 2005, Journal of Alzheimer's disease : JAD.

[23]  Jens C. Brüning,et al.  The role of insulin receptor signaling in the brain , 2005, Trends in Endocrinology & Metabolism.

[24]  D. Alkon,et al.  Insulin receptor signaling in long-term memory consolidation following spatial learning. , 2005, Learning & memory.

[25]  C. Mitchell,et al.  The SH2 domain containing inositol polyphosphate 5-phosphatase-2: SHIP2. , 2005, The international journal of biochemistry & cell biology.

[26]  H. Ishihara,et al.  Impact of SRC homology 2-containing inositol 5'-phosphatase 2 gene polymorphisms detected in a Japanese population on insulin signaling. , 2005, The Journal of clinical endocrinology and metabolism.

[27]  A. Artola,et al.  Insulin modulates hippocampal activity‐dependent synaptic plasticity in a N‐methyl‐d‐aspartate receptor and phosphatidyl‐inositol‐3‐kinase‐dependent manner , 2005, Journal of neurochemistry.

[28]  K. Flegal,et al.  Prevalence of overweight and obesity in the United States, 1999-2004. , 2006, JAMA.

[29]  M. Laakso,et al.  Association of metabolic syndrome with Alzheimer disease , 2006, Neurology.

[30]  A. D. de Craen,et al.  The metabolic syndrome is associated with decelerated cognitive decline in the oldest old , 2007, Neurology.

[31]  G. Wilcock,et al.  The metabolic syndrome and Alzheimer disease. , 2007, Archives of neurology.

[32]  C. Caruso,et al.  Alzheimer's disease and genetics of inflammation: a pharmacogenomic vision. , 2007, Pharmacogenomics.

[33]  A. Astell,et al.  Molecular connexions between dementia and diabetes , 2007, Neuroscience & Biobehavioral Reviews.

[34]  Domenico Lio,et al.  Inflammation, genes and zinc in Alzheimer's disease , 2008, Brain Research Reviews.

[35]  Sotirios Giannopoulos,et al.  Metabolic Syndrome and Alzheimer's Disease: A Link to a Vascular Hypothesis? , 2008, CNS Spectrums.

[36]  R. Pratley,et al.  Amyloid Precursor Protein Expression Is Upregulated in Adipocytes in Obesity , 2008, Obesity.

[37]  Suzanne Craft,et al.  The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. , 2009, Archives of neurology.

[38]  A. Sinclair,et al.  Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease , 2009, Neurology.

[39]  F. Panza,et al.  Is insulin resistant brain state a central feature of the metabolic-cognitive syndrome? , 2010, Journal of Alzheimer's disease : JAD.

[40]  B. Winblad,et al.  Diabetes, Alzheimer disease, and vascular dementia , 2010, Neurology.

[41]  I. Ferreira,et al.  Multiple defects in energy metabolism in Alzheimer's disease. , 2010, Current drug targets.

[42]  J. Francis,et al.  Central Adiposity, Systemic Inflammation, and the Metabolic Syndrome , 2010, Current hypertension reports.

[43]  J. Luchsinger.  Insulin resistance, type 2 diabetes, and AD , 2010, Neurology.

[44]  C. Caruso,et al.  Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. , 2010, Rejuvenation research.

[45]  I. Ferreira,et al.  Multiple Defects in Energy Metabolism in Alzheimers Disease , 2010 .

[46]  T. Uwano,et al.  The inositol phosphatase SHIP2 negatively regulates insulin/IGF-I actions implicated in neuroprotection and memory function in mouse brain. , 2010, Molecular endocrinology.